Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 21, 2007; 13(23): 3232-3236
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3232
Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3232
Table 1 Grading of the inflammatory activity in chronic hepatitis according to Ishak et al (the maximum possible scoring is 18)
| Score | |
| Portal inflammation | |
| None | 0 |
| Mild, some or all portal areas | 1 |
| Moderate, some or all portal areas | 2 |
| Moderate/severe, all portal areas | 3 |
| Severe, all portal areas | 4 |
| Periportal or periseptal interface hepatitis (“piecemeal necrosis”) | |
| Absent | 0 |
| Mild (focal, few portal areas) | 1 |
| Mild/moderate (focal, most portal areas) | 2 |
| Moderate (continuous around < 50% of tracts or septa) | 3 |
| Severe (continuous around > 50% of tracts or septa) | 4 |
| Focal parenchymal necrosis | |
| Absent | 0 |
| 1 focus or less per visual field of 100 × magnification | 1 |
| 2-4 foci per 100 × magnification | 2 |
| 5-10 foci per 100 × magnification | 3 |
| More than 10 foci per 100 × magnification | 4 |
| Confluent necrosis | |
| Absent | 0 |
| Focal confluent necrosis | 1 |
| Zone 3 necrosis in some areas | 2 |
| Zone 3 necrosis in most areas | 3 |
| Zone 3 necrosis and occasional portal-central bridging | 4 |
| Zone 3 necrosis and multiple portal-central bridging | 5 |
| Panacinar or multiacinar necrosis | 6 |
Table 2 Stages according to the METAVIR criteria (Bedossa et al)
| Stage 0 | No fibrosis |
| Stage 1 | Mild fibrosis (portal/periportal fibrosis, no septa) |
| Stage 2 | Moderate fibrosis (few septa) |
| Stage 3 | Severe fibrosis (many septa, no cirrosis) |
| Stage 4 | Cirrhosis |
Table 3 Clinical characteristics of patients with AIH before tacrolimus treatment
| Patient | Gender | Age | Prednisolone | Additional | HLA type | ALT | IgG | INR | Bilirubin | Albumin | Creatinine | Follow-up |
| No. | (yr) | dose | immonusupression | (U/L) | (g/L) | (μmol/L) | (g/L) | (μmol/L) | (mo) | |||
| 1 | F | 64 | 20 | MMF | N.A. | 271 | 15 | 1.1 | 9 | 37.8 | 88 | 37 |
| 2 | F | 32 | 20 | AZA | DR-3 | 156 | 29 | 1.6 | 30 | 28.0 | 71 | 20 |
| 3 | F | 49 | 20 | MMF | DR-4,15 | 109 | 18 | 1.1 | 13 | 34.7 | 85 | 34 |
| 4 | F | 20 | 40 | AZA | N.A. | 102 | 12.3 | 0.9 | 13 | 43.0 | 55 | 18 |
| 5 | F | 17 | 20 | AZA | DR-17, DQ2 | 475 | 30.2 | 1.0 | 146 | 39.1 | 59 | 13 |
| 6 | M | 16 | 80 | AZA | DR-7,17 | 154 | 16 | 1.5 | 8 | 37.1 | 65 | 17 |
| 7 | F | 55 | 25 | AZA | DR-4,13 | 100 | 17 | 1.1 | 58 | 37.1 | 49 | 12 |
| 8 | F | 49 | 20 | AZA | DR-4,7 | 202 | 10 | 1.2 | 15 | 42.2 | 66 | 12 |
| 9 | F | 32 | 20 | MMF | N.A. | 126 | 16 | 1.1 | 6 | 33.3 | 68 | 36 |
- Citation: Larsen FS, Vainer B, Eefsen M, Bjerring PN, Hansen BA. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13(23): 3232-3236
- URL: https://www.wjgnet.com/1007-9327/full/v13/i23/3232.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i23.3232
